BNP/CALL/EDWARDS LIFESCIENCES/110/0.1/16.01.26 | Market Closed - Bid/Ask 03:00:53 2024-05-17 EDT | After market 14:00:19 | |||
| 0.96 EUR | +1.05% |
|
0.92 | -4.17% |
| Current month | +14.46% | ||
| 1 month | -11.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.96 | +1.05% |
| 24-05-16 | 0.95 | +20.25% |
| 24-05-15 | 0.79 | +3.95% |
| 24-05-14 | 0.76 | -6.17% |
| 24-05-13 | 0.81 | -2.41% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 03:00 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PC610E |
| ISIN | DE000PC610E8 |
| Date issued | 2024-03-21 |
| Strike | 110 $ |
| Maturity | 2026-01-16 (609 Days) |
| Parity | 10 : 1 |
| Emission price | 1.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.35 € |
|---|---|
| Lowest since issue | 0.74 € |
| Spread | 0.02 € |
| Spread % | 2.15% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.11
USD
Average target price
95.9
USD
Spread / Average Target
+6.43%
- Stock Market
- Warrants
- Warrant
